A Two-Part Pilot Study of Dosing, Safety and Efficacy of Varenicline Initiated During an Acute Smoke-free Hospitalization and Continued Post-Hospitalization (VIP)

NCT01413516 Phase 2 COMPLETED Results posted

This Investigator Initiated Research Award (IIR Award #WS981308) is a two-part pilot study that aims to examine acceptability and feasibility of varenicline use during an acute (72-hr) smoke-free hospitalization (Part 1) and 4-weeks post-hospitalization (Part 2).

Details

Lead sponsor	Stanford University
Phase	Phase 2
Status	COMPLETED
Enrolment	17
Start date	2011-08
Completion	2014-10

Conditions

• Smoking Cessation

Interventions

• Smoking cessation counseling
• Placebo
• Varenicline

Primary outcomes

• 7 Day Point Prevalence Abstinence From All Forms of Tobacco — 4 weeks after beginning study
  Self report of being quit for 7 continuous days at the time of the 4-week follow-up survey confirmed by saliva cotinine or urine anabasine verification.

Countries

United States